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Nuclear Factor κB Inhibitors Alleviate
and the Proteasome Inhibitor PS-341
Exacerbates Radiation Toxicity
in Zebrafish Embryos
Borbala Daroczi,1 Gabor Kari,1 Qing Ren,1 Adam P. Dicker,1,3 and Ulrich Rodeck2,3
1
3

Departments of Radiation Oncology, and 2Dermatology and Cutaneous Biology, and
Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania

Reprinted with permission from the American Association of Cancer Research, “Nuclear factor κB
inhibitors alleviate and the proteasome inhibitor PS-341 exacerbates radiation toxicity in zebrafish
embryos”, Moleculaer Cancer Therapy, 2009;8(9), pages 2625-2634.

Abstract
Inflammatory changes are a major component of the normal tissue response to ionizing radiation,
and increased nuclear factor κB (NF-κB) activity is an important mediator of inflammatory responses.
Here, we used zebrafish embryos to assess the capacity of two different classes of pharmacologic agents
known to target NF-κB to modify radiation toxicity in the vertebrate organism. These were proteasome
inhibitors, including lactacystin, MG132, and PS-341 (Bortezomib/VELCADE), and direct inhibitors of
NF-κB activity, including ethyl pyruvate (EP) and the synthetic triterpenoid CDDO-TFEA (RTA401),
among others. The proteasome inhibitors either did not significantly affect radiation sensitivity of
zebrafish embryos (MG132, lactacystin) or rendered zebrafish embryos more sensitive to the lethal
effects of ionizing radiation (PS-341). Radiosensitization by PS-341 was reduced in fish with impaired
p53 expression or function but not associated with enhanced expression of select p53 target genes. In
contrast, the direct NF-κB inhibitors EP and CDDO-TFEA significantly improved overall survival of
lethally irradiated zebrafish embryos. In addition, direct NF-κB inhibition reduced radiation-induced
apoptosis in the central nervous system, abrogated aberrations in body axis development, restored
metabolization and secretion of a reporter lipid through the gastrointestinal system, and improved renal
clearance compromised by radiation. In contrast to amifostine, EP and CDDO-TFEA not only protected
against but also mitigated radiation toxicity when given 1 to 2 hours postexposure. Finally, four
additional IκB kinase inhibitors with distinct mechanisms of action similarly improved overall survival of
lethally irradiated zebrafish embryos. In conclusion, inhibitors of canonical pathways to NF-κB activation
may be useful in alleviating radiation toxicity in patients. [Mol Cancer Ther 2009;8(9):2625-34]

Introduction
Normal tissue damage limits the dose of ionizing radiation that can be safely administered to
treat neoplastic disease. A well-known example of this problem is inflammation of the oral
mucosa and of the lining of the gastrointestinal tract in tumor patients receiving chemotherapy or
radiation.1 Depending on the area of the body treated with radiation, other organ sites including
the lungs and the pericardium also manifest radiation-induced inflammation. A pervasive
feature of ionizing radiation–associated inflammation is the increased presence of proinflammatory
cytokines including tumor necrosis factor-α (TNF-α) and interleukin-6, both locally and in
the circulation.2 In contrast to intracellular regulators of the DNA damage response, these
and other inflammatory mediators act in a paracrine fashion affecting diverse cell types in the
tissue microenvironment or even at a distance.3 This circumstance highlights the necessity to
use animal models to investigate the relative contribution of inflammatory changes to the
overall response to radiation-induced cell and tissue injury in a multicellular organism.

In recognition of this need, we recently
established zebrafish embryos as a facile
vertebrate in vivo system to monitor the effects
of radiation protectors on normal tissues
during development.4
The nuclear factor κB (NF-κB) family of
transcription factors represents a diverse and
shared signaling mechanism activated during
cell stress responses.5 In addition, deregulated
NF-κB signaling has been implicated in the
malignant phenotype and treatment resistance
of select tumor forms.6-10 The canonical pathway
to NF-κB activation leads to IκB kinase
β (IKKβ)-dependent phosphorylation and
subsequent proteasomal degradation of the
NF-κB inhibitor IκB, increased nuclear presence
of NF-κB dimers, and enhanced NF-κB–
dependent transcriptional activity.5
Whole-body radioprotection through antiinflammatory agents has very recently been
shown in animal models. Specifically, certain
triterpenoids (CDDO and derivatives thereof)
have been shown to selectively protect normal
mouse tissues against the deleterious effects of
ionizing radiation.11 Furthermore, ethyl pyruvate
(EP), a derivative of the end product of
glycolysis, similarly protects normal cells against
the deleterious effects of radiation both in vitro
and in mice.12 Among other molecular targets,
both drugs inhibit activation of NF-κB.
EP inhibits NF-κB signaling through direct
molecular interaction with a reactive cysteine of
the p65 subunit of NF-κB13 whereas CDDOTFEA binds to a reactive cysteine (Cys179) of
IKKα, thus inhibiting its kinase activity.14
However, these drugs also target other signaling
molecules and pathways of potential relevance
to the radiation response, including signal
transducers and activators of transcription
3 and Jaks.15, 16 In addition to these agents
proteasome inhibitors have been shown to
inhibit NF-κB–dependent transcription, and
one of these (PS-341; Bortezomib; VELCADE)
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has been Food and Drug Administration–approved for clinical use
in patients afflicted with multiple myeloma (for review see refs.17, 18).
It is presently unknown whether and how proteasome inhibitors affect
whole-body radiation sensitivity.
Collectively, these results raised the question whether inhibition of
NF-κB activity by different pharmacologic agents contributes to the
protection of normal cells and tissues against damage induced by ionizing
radiation. Here, we addressed this issue using zebrafish embryos as an
in vivo model system. We observed that the NF-κB inhibitors EP and
CDDO-TFEA afforded protection to zebrafish embryos against the
lethal effects of radiation in the pre-exposure and postexposure settings,
i.e., when administered hours after radiation exposure. Radiation
protection extended to multiple organ sites including the gastrointestinal
system and, importantly, was also observed when using additional IKK
inhibitors with different modes of action. In contrast, several proteasome
inhibitors, including PS-341, did not protect against, but rather moderately
exacerbated radiation-associated normal tissue toxicity in zebrafish
embryos. These results predict a favorable therapeutic index for the use
of inhibitors of canonical pathways to NF-κB activation in combination
with radiation therapy.

Materials and Methods
Embryo Harvesting and Maintenance
Zebrafish were mated in embryo collection tanks. Viable embryos were
washed and sorted (25 embryos per 60-mm dish) at the one- to twocell developmental stage, and maintained under normoxic conditions at
28.5°C to enable normal development. Embryo medium was changed at
24, 72, and 120 h postfertilization (hpf). All procedures using live zebrafish
were approved by the Institutional Animal Care and Use Committee at
Thomas Jefferson University. In select experiments, embryos (24 hpf)
were dechorionated by placement in embryo medium supplemented
with 50 μg/mL pronase (Sigma) for approximately 10 min at room
temperature, then gently agitated with a plastic pipette until the embryos
were liberated from the disrupted chorions. After dechorionation, the
embryos were rinsed thoroughly with embryo medium, and placed
in fresh embryo medium.
Radiation Exposure and Drug Treatments
Pharmacological agents [EP was kindly provided by CDDO-TFEA
was from Reata Pharmaceuticals; IKK inhibitor 2 (Weldelolactone),
IKK inhibitor 3 (BMS-345541), IKK-2 inhibitor 4, and IKK-2 inhibitor
5 (IMD-0354) were from Calbiochem; MG132 was from Sigma; PS-341
was from Millennium Pharmaceuticals; and lactacystin was from
Calbiochem) were dissolved in embryo medium containing <0.1% DMSO.
Embryo medium was used as a vehicle control in all experiments. Unless
stated otherwise embryos were exposed to ionizing radiation ranging in
dose from 0 to 20 Gy at 24 hpf using an X-ray machine (Gulmay Medical)
or a 137Cs radiation source. Toxicity analyses for EP (<10 mmol/L),
CDDO-TFEA (<10 μmol/L), PS-341 (<10 μmol/L), MG132 (<50
μmol/L), or lactacystin (<10 μmol/L) were conducted by monitoring
survival and development of zebrafish embryos for 7 d in the absence of
radiation. To determine modulation of radiation-induced toxicity, EP
(1 mmol/L) or CDDO-TFEA (1 μmol/L) was added to embryos either
1 h before or up to 3 h after radiation exposure at 24 hpf. The proteasome
inhibitors were added to zebrafish embryos 1 h prior to ionizing radiation.
After irradiation, zebrafish embryos were maintained at 28.5°C for up
to 7 d postfertilization to monitor effects of treatments on survival,
morphology, and organ-specific toxicity.
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Analysis of Treatment Effects on Zebrafish Survival and
Gross Morphology
Dechorionated embryos at 72 hpf were anesthetized with a 1:100 dilution of
4 mg/mL tricaine methanesulfonate (Sigma) and immobilized by placing
them on 3% methylcellulose on a glass depression slide. Morphology
was assessed visually using a light transmission microscope (Olympus
BX51, Olympus) at 40 to 100× magnification, and representative images
recorded using a QIMAGING camera and QIMAGING Advanced
software (QIMAGING Diagnostic Instruments). Similarly, survival of
embryos was assessed visually at 24-h intervals up to 7 days by light
microscopy. The criterion for embryonic survival was the presence of
cardiac contractions.
Apoptosis Assay
Zebrafish embryos were incubated for 1 h in embryo medium containing
modifiers of the radiation response and exposed to 20 Gy at 24 hpf. Six
hours after radiation exposure, embryos were stained for 15 min using 5
μg/mL of acridine orange dye (Sigma) and rinsed five times with embryo
medium as described previously.19 Zebrafish embryos were imaged with
QIMAGING camera and iVision software; the images were analyzed
using ImageJ software.
Detection of ROS
Reactive oxygen species (ROS) levels were measured in dechorionated
zebrafish embryos in 96-well plates. Embryos (1 embryo/well) were
treated with either vehicle (embryo medium) or EP (1 mmol/L) or
CDDO-TFEA (1 μmol/L) in the presence of 5-(and-6)-chloromethyl2´,7´-dihydrodichlorofluorescein diacetate (CM-H2DCFA; 500 ng/mL;
Molecular Probes) followed by radiation exposure at 24 hpf. The
average fluorescence emission at 530 nm following excitation at 490
nm was detected immediately and 2 h after ionizing radiation exposure
using a microplate fluorescent reader (BIO-TEK FL 600, BIO-TEK
Instruments Inc.). To account for radiation-induced ROS in the embryo
medium results were corrected by subtraction of values obtained in wells
not containing fish in the presence and absence of pharmacologic agents.
Renal Function Assay
Time-dependent clearance of tetramethylrhodamine-labeled 10-kDa
dextran (Molecular Probes) was determined as described previously with
minor modifications.20 Briefly, zebrafish embryos at 24 hpf were exposed to
ionizing radiation and maintained in embryo medium. At 72 hpf
embryos were anesthetized using a 1:100 dilution of 4 mg/mL tricaine
methanesulfonate (Sigma) and dorsally positioned on 3% methylcellulose
gel. Tetramethylrhodamine-labeled 10-kDa dextran was injected into
the cardiac venous sinus; embryos were kept at 28.5°C, and imaged at 1
and 24 h following microinjection. The average fluorescence emission at
590 nm following excitation at 570 nm was detected at the center of the
cardiac area, and the relative intensity was measured using a Leica microscope (Leica Mikroskopie & Systeme GmbH). Images were transformed
into grayscale and evaluated with NIH ImageJ software as described.20
Morphologic Analysis of the Gastrointestinal System
The functional and morphologic integrity of the developing gastrointestinal system was assessed in zebrafish embryos using PED6, a
fluorescent reporter of phospholipase A2 (PLA2) activity. PED6 is a fluorogenic substrate for PLA2, which contains a BODIPY FL dye-labeled acyl
chain and a dinitrophenyl quencher group.21 The cleavage of the dyelabeled acyl chain by PLA2 within cells lining the intestine unquenches the
dye and leads to detectable fluorescence in the lumen of the developing
gastrointestinal tract. PED6 was added to zebrafish embryos at 5 dpf
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followed by imaging the fish at 6 dpf with the average fluorescence
emission at 540 nm excitation at 505 nm. Images were taken at 6 dpf
using a Leica microscope and analyzed using the ImageJ software.
Histopathology and Evaluation of Tissue Morphology
Zebrafish embryos were evaluated histopathologically for morphologic
alterations induced by radiation exposure and potential radioprotective
effects of EP and CDDO-TFEA with special emphasis on the gastrointestinal morphology. Briefly, embryos at 24 hpf were exposed to 0 or 12
Gy in the presence or absence of either CDDO-TFEA or EP administered
1 h prior to ionizing radiation. Embryos were sacrificed, fixed by immersion in 4 % paraformaldehyde for 24 h, and then rinsed and placed in 10×
PBS for another 24 h. Sections were embedded in paraffin, and coronal,
transverse, and sagittal whole-body sections (4 μm thickness) were generated. All sections were stained with H&E, mounted on glass slides, and
examined by light microscope; representative images were taken using a
QIMAGING camera and iVision software.
NF-κB Reporter Assay
NF-κB reporter assay was done as described by us previously 22 with
minor modifications. HeLa cells were seeded at 7.5 × 104/mL in DMEM
supplemented with 10% fetal bovine serum. The cells were cotransfected
with the pSEAP2-NF-κB vector (BDBioSciences) encoding a secreted
form of human placental alkaline phosphatase driven by a NF-κB–
responsive promoter and a β-galactosidase expression vector for control
purposes. Forty-eight hours posttransfection, different NF-κB inhibitors
(0.5 μmol/L velcade, 5 μmol/L MG-132, 1 mmol/L EP, 1 μmol/L CDDO)
were added to the cells in serum-free media for 24 h. NF-κB–dependent
transcription in the absence and presence of recombinant TNF-α (10 ng/
mL; R&DSystems) was determined 72 h posttransfection using the Great
EscAPe SEAP Reporter System 3, which is based on detection of secreted
alkaline phosphatase in cell supernatants normalized to β-galactosidase
activity using the luminescent β-gal detection kit (BDBiosciences).
Reverse Transcription PCR Analysis
Zebrafish total RNA was isolated from 100 embryos per experimental
condition at 30 hpf (6 h post radiation) using the RNeasy mini kit
(QIAGEN Sciences) and stored at −80°C. For reverse transcription, total
RNA was annealed with Oligo(dT) primer (Roche) at 70°C for 5 min
followed by the incubation at 42°C for 1 h. Reverse transcription reaction
products were boiled for 2 min followed by incubation on ice for 2 min
before use. Primer sequences used for amplification of bax, mdm2, p21/
waf-1, and β-actin zebrafish sequences are provided in Supplementary
Table S1. PCR reaction conditions were 94°C, 60°C, 72°C for 30 s, 30 s, 1
min, respectively, and 35 cycles with 7 min extension time after the last cycle.
Thermo Fisher Scientific Taq-polymerase was used in 50 μL PCR reaction
mix containing 1 μL reverse transcription reaction. PCR reactions were
analyzed by 1.5% agarose gel electrophoresis.
Statistical Analysis
All experiments were done at least three times with at least 75 embryos
total per experimental group. To determine statistically significant
differences between groups χ2 tests were done.

Results
Proteasome Inhibitors Radiosensitize Zebrafish Embryos
The proteasome inhibitor PS-341 (Bortezomib/VELCADE) is presently
the only Food and Drug Administration–approved drug with wellcharacterized inhibitory effects on NF-κB activity.18 PS-341 is a small,
cell-permeable molecule inhibiting proteasome activity in a reversible
manner. In addition to reducing the activation state of NF-κB by inhibiting

proteasomal degradation of IκB, PS-341 affects many other pathways
and targets, leading to high expression levels of several proapoptotic
proteins in certain experimental conditions.23 In vitro, PS-341 has been
found to enhance antitumor cell effects of select chemotherapeutic
agents6,24, tumor cell targeting antibodies25, and ionizing radiation26.
Yet, little is known about the combined effects of PS-341 and ionizing
radiation on normal cells and tissues of vertebrate organisms. To address
this issue we used PS-341 in zebrafish embryos exposed to high doses of
ionizing radiation as described by us previously.4, 27, 28 We first established
that treatment of zebrafish with PS-341 alone (dose range, 0–10 μmol/L)
was nontoxic as assessed by embryo survival and gross morphology during
the first 7 days after fertilization (Supplementary Fig. S1). In contrast, PS-341
(1 μmol/L) markedly sensitized zebrafish embryos to the lethal effects of
ionizing radiation when administered 1 hour prior to radiation (Fig. 1A).
In these experiments zebrafish embryos were exposed at 24 hpf to 20 Gy,
previously determined to kill 50% of irradiated zebrafish embryos by day
7 of development.27 In HeLa cells, at the same concentration (1 μmol/L)
PS-341 abrogated the TNF-α–induced NF-κB activity, whereas it did not
significantly affect the basal activity (Supplementary Fig. 2A and B).
To ascertain whether radiation sensitization by PS-341 could be replicated
using other inhibitors of the proteasome we next tested the effects of
MG132, a nonboronated small molecule inhibitor of the 26S proteasome,29
on zebrafish survival in the presence and absence of ionizing
radiation. Similar to PS-341, MG132 was remarkably nontoxic when
applied as a single agent to zebrafish embryos (dose range, 0–50 μmol/L) yet
efficiently inhibited TNF-α–induced but not the baseline NF-κB activity
in HeLa cells when used at 5 μmol/L (Supplementary Fig. 2A and B).
At this concentration, however, MG132 marginally sensitized zebrafish
embryos to the lethal effects of 20 Gy ionizing radiation albeit to a lesser
degree than PS-341 (Fig. 1B). An irreversible proteasome inhibitor
(lactacystin) at a nontoxic concentration (5 μmol/L) also slightly radiosensitized zebrafish embryos in a manner similar to MG132 (Fig. 1C).
These results show that several proteasome inhibitors do not protect normal
cells and tissues in the developing fish larvae against the deleterious
effects of radiation. As p53 is a major target of proteasomal degradation
and enhances ionizing radiation–associated tissue damage in mice30–32
and zebrafish33, 34 we asked whether the deleterious effects of proteasome
inhibitors could be linked to p53 stabilization and subsequent induction
of target genes. Consistent with our earlier observations, ablating
p53 expression by antisense morpholino oligodeoxynucleotide35 or p53
function by PFT-α (1 μmol/L) given to zebrafish embryos at 24 hpf34
markedly improved zebrafish survival after radiation either alone or in
combination with PS-341 (not shown). However, reverse transcriptionPCR analysis did not reveal increased steady-state mRNA levels of
the p53 targets p21/WAF1, bax, or the zebrafish ortholog of mdm2 in
PS-341–treated embryos whereas ionizing radiation led, as expected, to
elevated transcript levels for these genes (Supplementary Fig. S3). Thus,
the molecular target(s) responsible for radiosensitization by PS-341 and
their relationship, if any, to the p53 response remain to be identified.
Radiation Protection of Zebrafish Embryos by the NF-κBp65
Inhibitor Ethyl Pyruvate
In consideration of the fact that proteasome inhibitors affect multiple
intracellular pathways in addition to NF-κB and to pinpoint the functional
contribution of NF-κB to the radiation response of zebrafish embryos, we
tested the effects of a series of pharmacologic inhibitors of NF-κB activity
with different mechanisms of action on the radiation response of zebrafish
embryos. Reducing NF-κB activity by expression of upstream regulator
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Figure 1. Effects of the proteasome inhibitors PS-341 (A), MG132 (B), and lactacystin (C) on the radiation sensitivity of zebrafish embryos. Embryos
were irradiated at 24 hpf and survival was scored every day up to 7 dpf. Results shown represent mean ± SD of triplicate experiments. *,
statistically significant difference in survival at 6 to 7 dpf.
IκB has previously been shown to cause severe embryonal malformations
in zebrafish36, 37 and, thus, was not further considered. In addition,
knockdown of the NF-κBp65 subunit by antisense morpholinos similarly
caused severe morphologic defects (no tail phenotype) during the first 3
days of development (Supplementary Fig. S4) consistent with published
results37 and, thus, was not informative in the context of assaying the
radiation response. Instead, we used pharmacologic inhibitors that
disrupt the canonical pathway to NF-κB activation and could be used at
concentrations that do not interfere with embryonal development. First,
we tested EP, a ROS scavenger and inhibitor of NF-κBp6538. EP inhibits
the DNA binding activity of NF-κBp65 by binding to a reactive cysteine
in the DNA binding site (Cys 38) of NF-κBp6513, which is shared between
humans and zebrafish (Supplementary Fig. S2C). EP has very recently
been shown to mitigate deleterious effects of total body irradiation
in mice12. We observed that EP similarly not only protected against
but also mitigated lethality associated with whole body irradiation of
zebrafish embryos (Fig. 2A, C, and F). EP was administered at various
time points ranging from 1 hour prior to radiation exposure to 3 hours
postirradiation. The ROS scavengers amifostine and DF-1 served as
positive controls in these experiments as we observed marked protection
of embryos by these two compounds in earlier work.4, 27 Whereas
amifostine and DF-1 afforded protection against deleterious effects of
ionizing radiation when administered prior to or concurrent with
radiation, neither compound could mitigate the lethal effects of radiation
when given beyond 15 minutes after ionizing radiation27. In marked
contrast, EP administered up to 2 hours after radiation significantly
reduced ionizing radiation–associated lethality (Fig. 2F).
The IKK Inhibitor CDDO-TFEA Mitigates Radiation Effects in
Zebrafish Embryos
To further address the relevance of NF-κB activation in modulating
radiation sensitivity of zebrafish embryos we used CDDO-TFEA that
inhibits NF-κB signaling by interacting with Cys179 of IKKβ, inhibiting
its activity and preventing phosphorylation and proteasomal degradation
of IκB39 and, thus, through a molecular mechanism distinct from EP. The
amino acid sequence around this reactive Cys179 is also highly conserved
in zebrafish (Supplementary Fig. 2C). CDDO-TFEA protected against
and mitigated overall lethal effects of radiation in zebrafish embryos
in a manner similar to EP (Fig. 2B, D , and F). We next determined whether
mitigation of radiation effects cosegregated with the capacity of the
compounds under investigation to act as ROS scavengers. This was based
on the findings that, in addition to directly binding to IKKβ, CDDO has
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been described to induce expression of enzymes catalyzing antioxidant
reactions in peripheral blood mononuclear cells due to increased nuclear
accumulation of Nrf2, an oxidant-responsive bZIP transcription factor.40, 41
Whereas EP is an effective ROS scavenger in irradiated zebrafish embryos,
CDDO-TFEA did not reduce ROS levels measured 2 hours after radiation
exposure (Supplementary Fig. S5). Thus, at least the effect of CDDO-TFEA
on radiation mitigation cannot be ascribed to ROS scavenging, whereas
in the case of EP, ROS scavenging and NF-κB inhibition may be jointly
responsible for the beneficial effects of EP in the mitigation setting. Of note,
the ROS scavengers with no known effect on NF-κB signal transduction
(amifostine and DF-1) do not mitigate radiation effects if administered
beyond 15 minutes after ionizing radiation.27 To further probe whether
IKK inhibition is radioprotective we tested four additional small
molecule IKK inhibitors, i.e. Wedelolactone (IKK inhibitor 2), BMS345541 (IKK inhibitor 3) and IKK-2 inhibitors 4 and 5. All four agents
protected zebrafish embryos against the lethal effects of radiation in a
manner similar to CDDO-TFEA and EP (Fig. 2E). Moreover, unlike EP
or CDDO-TFEA, these agents are not known to have antioxidant properties
and primarily inhibit IκBα phosphorylation by IKKβ (i.e., IKK-2).
On balance, these results suggest that prolonged and excessive activation of
the canonical NF-κB pathway is a major contributor to radiation toxicity
in the developing vertebrate organism and that inhibiting this pathway
may protect the organism against deleterious effects of radiation.
Organ-Specific Radiation Protection by CDDO-TFEA and EP
Having established that EP and CDDO-TFEA provide whole-body protection against lethal doses of radiation and in consideration of the fact
that these compounds are in preclinical development, we next determined
organ-specific radiation protective effects of these two NF-κB inhibitors.
First, we assessed, by acridine orange staining, organism-wide apoptosis
in zebrafish embryos determined 6 hours after radiation. Consistent
with earlier reports 33, we observed increased acridine orange staining
in the central nervous system and along the body axis of irradiated
embryos. Both NF-κB inhibitors markedly reduced radiation-induced
acridine orange staining (Fig. 3). We previously reported that ionizing
radiation compromised zebrafish kidney function as determined by delayed
excretion of a fluorescent dextran injected intracardially.27 Treatment with EP
but not CDDO-TFEA significantly reversed the effect of ionizing radiation on dextran clearance of irradiated embryos to near normal levels,
suggesting protection against ionizing radiation–induced kidney damage
(Fig. 4). It is currently unknown whether this effect reflects differences
in ROS scavenging capacity between the two compounds as described

Studies

B

E
100

25

0 Gy
Vehicle
CDDO-TFEA (1 µM) 20 Gy

25
0

0

1

2

3

4

5

6

7

8

0

1

2

Days Post Fertilization

3

4

5

6

7

50
25
0

8

0 Gy

0

50

75

Days Post Fertilization

C

D
100

IR

50
0 Gy
Vehicle
Ethyl Pyruvate (1mM) 40 Gy

25

75

IR

50
0 Gy
Vehicle
CDDO-TFEA (1 µM) 40 Gy

25

20 Gy

F

0

0
0

1

2

3

4

5

6

7

0

1

Days Post Fertilization

2

3

4

5

6

Days Post Fertilization

Figure 2. Protection against and mitigation of lethal effects of radiation by direct NF-κB
inhibitors. Differential survival of zebrafish embryos pretreated with EP (A and C) or
CDDO-TFEA (B and D) and exposed to either 20 or 40 Gy as indicated. E, radiation protection
of zebrafish embryos exposed to 20 Gy and treated for 1 h prior to irradiation with different
IKK inhibitors. F, increased survival of irradiated (20 Gy) zebrafish embryos treated with EP
(1mmol/L) or CDDO-TFEA (1 μmol/L) 2 h post radiation at 24 hpf. Survival was scored at 7
dpf. All results shown represent mean ± SD of triplicate experiments.*, statistically significant
differences in survival at 7 dpf between drug-treated and vehicle-treated groups.
above (Supplementary Fig. S5) or is due to differences in pharmacokinetics
or pharmacodynamics. In addition, radiation of zebrafish embryos is
associated with a high incidence of a body axis malformation called “curly-up”
to describe aberrant dorsal curvature of the fish tail. Both CDDO-TFEA
and EP reduced the incidence of curly-up significantly (Fig. 5).
Finally, we determined the effects of radiation on the developing
gastrointestinal system. This was done in consideration of several prior
reports suggesting that NF-κB activation protects the gastrointestinal
tract of higher vertebrates against acute radiation damage.42, 43 Radiation
protection of the gastrointestinal system was determined in several ways.
First, we assayed overall gastrointestinal function by scoring “long-term”
survival of fish irradiated in the presence and absence of EP or CDDOTFEA (up to 15 dpf). Fish larvae become dependent on external food
sources at approximately 6 dpf when the contents of the yolk sac are
depleted. Significant functional damage to the gastrointestinal system
will thus lead to death by starvation within 10 days after conception.19
Conversely, survival of fish beyond two weeks indicates establishment
of a functionally adequate gastrointestinal system. Both EP and CDDOTFEA increased extended survival of zebrafish larvae (Supplementary
Fig. S6) although this effect was statistically significant only in the case
of CDDO-TFEA. To address the combined effects of radiation and EP
or CDDO-TFEA treatment on the developing gastrointestinal system
further, we determined gastrointestinal lumen formation by use of a
fluorescent reporter (PED6; ref. 21) that is metabolized and excreted
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through the gastrointestinal system. This analysis revealed severely
impaired lumen formation of the gastrointestinal system induced by
ionizing radiation (15 Gy) and partial restoration of lumen formation and
fluorescent dye excretion by treatment with either EP or CDDO. These
functional results were complemented by examining the histologic
appearance of the gastrointestinal system 5 days after radiation exposure
in the presence and absence of the NF-κB inhibitors under investigation (Fig. 6). The hindgut mucosal epithelium immediately proximal to
the cloaca revealed distinct cellular changes associated with sublethal
ionizing radiation exposure (12 Gy), including irregular shape and
disorganization of the columnar absorbing cells with redistribution of
nuclei away from the basal orientation. In addition, decreased goblet cell
numbers were observed. By contrast, EP and CDDO-TFEA pretreatment
of irradiated embryos restored, in part, the columnar structure of
absorbing cells and basal location of nuclei.

Discussion
Our results show that 6 of 6 pharmacologic inhibitors with different
chemical structures and mode of actions inhibit the canonical pathway
of NF-κB activation (consisting of IKKβ/IκB/NF-κBp65) and provide
protection against radiation-induced overall lethality and damage to
multiple organ systems of the developing zebrafish. By contrast, 3 of 3
proteasome inhibitors did not afford radiation protection, but radiosensitized zebrafish embryos to the lethal effects of ionizing radiation.
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Taking into account that each of the pharmacologic agents used in this
study is likely to affect targets other than NF-κB, it is remarkable that
radioprotection cosegregated with interference with activation of the
canonical pathway to NF-κB. This observation suggests that NF-κB may
be the relevant target for radiation protection by pharmacologic IKK/
NF-κB inhibition.
Currently, there is no consensus about the functional contribution of
NF-κB activation to the radiation response.44 Abundant reports of
radiosensitization of tumor cells in vitro and in vivo by NF-κB inhibition
are contrasted by relatively few such reports dealing with normal cells.
The use of genetically engineered mouse models to monitor NF-κB
dysfunction in normal tissues has been limited due to embryonal lethality
observed in IKKβ45 and NF-κBp6546 knockout animals. In cases where
either conditional knockouts were made or transgenic mice were gener-

A

ated by forced expression of dominant negative regulators to modulate
NF-κB activation, the interpretation of results is further complicated by
compensatory adjustments of homeostasis (for review see ref. 47). The
present study sidesteps the problems inherent to using genetic models
by examining the effects of pharmacologic agents used at concentrations that reduce but do not abrogate NF-κB activity. The ease of our
“assay system,” i.e., observation of overall effects of ionizing radiation
on zebrafish survival as well as effects on specific target organs, allowed
us to monitor the effects of drug classes grouped according to target
specificity and mechanisms of action. This approach had the advantage
to minimize confounding effects due to unknown, off-target effects
of any pharmacologic agent. By contrast, and as expected, ablating
NF-κB activity by targeting IKKβ or NF-κBp65 expression using antisense approaches produced a dramatically different outcome as these
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Figure 4. Effects of EP and CDDO-TFEA
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Figure 3. Reduction of organism-wide apoptosis by EP and CDDO-TFEA treatment
preradiation and postradiation. Acridine orange (AO) staining of whole embryos was done
6 h postradiation at 30 hpf. A, representative examples of control or irradiated fish revealing
strong AO staining in the central nervous system and along the body axis induced by radiation
(20 Gy). Regions selected for quantitative evaluation are boxed. B, reduced AO staining in
CDDO-TFEA- and EP-treated embryos exposed to ionizing radiation. C, PS-341 or MG132
treatment does not significantly affect AO staining of embryos exposed to ionizing radiation.
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interventions were associated with embryonic lethality even in the
absence of genotoxic stress (see Supplementary Fig. S4 and ref. 46). This
result is consistent with the view that inhibition of excess NF-κB activity
after lethal irradiation is beneficial whereas blocking NF-κB expression
and/or activation altogether, as in genetic knockout/knockdown models,
is deleterious (even in the absence of radiation). This contention is further supported by our finding that EP and CDDO-TFEA at the nontoxic
concentration used here disrupted TNF-α–induced NF-κB activation but
not basal NF-κB activity in HeLa cells in vitro (Supplementary Fig. S2).
Importantly, CDDO-TFEA and EP not only protected against but also
mitigated the lethal effects of radiation. This result is of interest as it
points to the importance of sustained NF-κB activation consistent with
inflammatory responses rather than the burst of NF-κB activity observed
immediately after radiation exposure. It remains to be seen whether
other anti-inflammatory agents may be used to mitigate radiation damage to normal tissues in the developing embryo.
Interestingly, radiation protection of zebrafish embryos by NF-κB inhibitors extended to the gastrointestinal system whereas previous work using
genetically modified mice42 and the TLR5 ligand flagellin43 has implicated
NF-κB activation in radiation protection of gastrointestinal stem cells. The
reason(s) for this difference are unclear at this point. However, the TLR5
ligand flagellin exerts pleiotropic stimulatory effects on multiple signaling
pathways that include NF-κB but also p38, Erk/mitogen-activated protein
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Figure 5. EP and CDDO-TFEA
alleviate radiation-induced malformations of the body axis. A, representative
micrographs showing dorsal curvature
(“curly-up”; cup) in irradiated (20
Gy) embryos at 72 hpf relative
to control nonirradiated fish embryos.
B, quantification of curly-up incidence
in CDDO-TFEA- and EP-treated fish
relative to vehicle-treated controls.
*, statistically significant differences
between the experimental groups
indicated by brackets.

kinase, and potentially, signal transducers and activators of transcription.48
It has not been reported which of these multiple effects alone or in combination is at cause for radioprotection provided by flagellin.43 In addition,
the NF-κB inhibitory effects of both EP and CDDO-TFEA are completely
reversible, whereas genetic ablation is not and this circumstance
could affect outcomes of NF-κB activation in reference to gastrointestinal
function. Our findings are further consistent with the view that excessive
NF-κB activation, as observed in the context of chronic inflammation, is
potentially deleterious to the gastrointestinal system49 and, thus, downmodulating NF-κB activity but not ablating it altogether can be advantageous in certain settings.50 Although the details of these diverse outcomes
in different model systems remain to be sorted out, our results clearly
show that reducing NF-κB activity with a variety of compounds with
different mechanisms of action diminishes radiation-induced damage to
several organ systems in the developing zebrafish embryo.
In conclusion, the most salient finding of this study is that direct inhibitors
of NF-κB activity provided effective protection and mitigation against
overall lethality and specific organ damage caused by ionizing radiation
in zebrafish embryos. Direct NF-κB inhibitors also exert antineoplastic
effects in select model systems as shown extensively for CDDO-TFEA
and derivatives thereof.51–57 These findings are consistent with a
favorable therapeutic window for NF-κB inhibitors when used in
combination with radiation and, potentially, chemotherapeutic drugs.

Figure 6. Effects of EP and CDDOTFEA on radiation-induced alterations of the gastrointestinal system.
A, improved PLA2 activity and
gastrointestinal lumen formation
in irradiated zebrafish treated
with either EP or CDDO-TFEA.
Dequenched fluorescence reflects
endogenous PLA2 activity and
transport of cleavage products through
the lumen of the developing gastrointestinal system. B, quantitative
evaluation of gastrointestinal lumen
formation as determined by fluorescent
dye content at 6 dpf. C, representative
histologic sections of hindgut
proximal to the cloaca at 6 dpf [5 d
post (12 Gy)].
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Purpose: The tumor growth kinetics of the human LoVo colorectal xenograft model was assessed
in response to vandetanib, an orally available receptor tyrosine kinase inhibitor, radiotherapy (RT),
or irinotecan (CPT-11), as single therapies and in combination.
Methods and Materials: LoVo cells were injected subcutaneously into the right hind limb
(5x106 cells in 100μL phosphate-buffered saline) of athymic NCR NUM mice and tumors were
grown to a volume of 200–300mm3 before treatment. Vandetanib was administered at 50 mg/kg
daily orally for 14 days starting on Day 1. RT was given as three fractions (3x3 Gy) on Days 1,
2, and 3. CPT-11 was given at 15 mg/kg intraperitoneally on Days 1 and 3. Tumor volumes were
measured on a daily basis and calculated by measuring tumor diameters with digital calipers in
two orthogonal dimensions.
Results: All three single treatments (vandetanib, CPT-11, and radiation) significantly slowed
LoVo colorectal tumor growth. Vandetanib significantly increased the antitumor effects of CPT-11
and radiation when given in combination with either of these treatments. These treatment
combinations resulted in a slow tumor growth rate during the 2 weeks of vandetanib administration.
The triple combination of vandetanib, CPT-11, and radiation produced the most marked improvement in response as observed by measurable shrinkage of tumors during the first week of treatment.
Conclusions: The tumor growth delay kinetics observed in this study of the LoVo colorectal
model suggest concurrent and sustained post-sequencing of vandetanib with cytotoxic therapy
may be beneficial in tumors of this type. ©2009 Elsevier Inc.

Key Words: Vandetanib, Radiotherapy, CPT-11, LoVo colorectal cancer,
Angiogenesis inhibitor.

Introduction
Colorectal cancer (CRC) remains one of the leading causes of mortality worldwide. In recent years,
the most widely used chemotherapy for metastatic CRC, fluoropyrimidine (5-fluorouracil [5-FU]) in
combination with folinic acid, has been combined with newer, highly active cytotoxic agents. Among
these agents is the DNA topoisomerase I inhibitor, irinotecan (CPT-11),1 a potent DNA-targeting
drug used in patients with CRC that is refractory to treatment with fluorouracil and leucovorin.
This cytotoxic agent is, in turn, being combined with new molecular therapies targeting the tumor
vasculature and key signaling pathways controlling tumor cell proliferation, angiogenesis, and
survival in CRC. In this regard, the epidermal growth factor receptor (EGFR) plays an important
role in CRC tumor growth and progression,2 and cetuximab, a monoclonal antibody specific for
EGFR, has been approved for use in combination with CPT-11 in patients with EGFR-expressing CRC
refractory to CPT-11–based chemotherapy.3 In addition, bevacizumab, a monoclonal antibody

specific for vascular endothelial growth
factor (VEGF-A), a key player in tumor
angiogenesis in CRC as well as other solid
tumors, has been approved for the treatment
of metastatic CRC in combination with
intravenous 5-FU–based chemotherapies.4
Despite recent improvements in treatment
for CRC, a need still remains to improve the
performance of existing treatments and to
establish the optimum scheduling and dosing
of combined therapies.
Vandetanib (ZACTIMA) is an oral receptor
tyrosine kinase inhibitor that, in recombinant
enzyme assays, demonstrates potent activity
against vascular endothelial growth factor
receptor-2 (VEGFR-2) tyrosine kinase (the half
maximal inhibitory concentration [IC50]=40
nmol/L) with additional activity against
EGFR (IC50=500 nmol/L) and the rearranged
during transfection (RET) tyrosine kinases
(IC50=130nM) tyrosine kinases.5–8 Vandetanib
has orphan-drug status in the United States
and Europe for medullary thyroid cancer
(in which RET activity is important) and is
in Phase III development in non–small-cell
lung cancer and medullary thyroid cancer.
Phase II studies are ongoing to investigate its
efficacy in other tumor types, thyroid cancer,
hepatocellular carcinoma, and glioblastoma.
Vandetanib has been shown to enhance the
efficacy of radiotherapy in subcutaneous and
orthotopic tumor xenograft models.9–13 The
combination of vandetanib, radiation, and
current chemotherapeutic agents used in CRC
treatment has not been studied. Preclinical
demonstration of efficacy of a combination
protocol with novel agents plus radiation
is usually considered crucial before clinical
evaluation. The purpose of the present study was
to examine the effect of vandetanib on the radiation response of a colorectal tumor model when
administered in combination with CPT-11. It was
hypothesized that simultaneous inhibition of
VEGFR and EGFR by vandetanib in combination
with the cytotoxic agent CPT-11 would interact
to enhance radiation response and tumor control
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in the human LoVo colorectal tumor cell model. The LoVo colorectal model
expresses activated EGFR14, 15 and is highly vascularized and therefore is an
appropriate model to test the hypothesis.

Methods and Materials
Animal and tumor model
LoVo cell suspensions (5x106 cells in 100 μL phosphate buffered saline)
were implanted subcutaneously into the right hind limbs of 6- to 8week-old athymic NCR NUM mice (Taconic Farms, Hudson, NY). A
subcutaneous xenograft model was chosen to facilitate radiation dosing and ease of tumor measurements. Tumors were allowed to grow for
approximately 25 days, until reaching an approximate volume of 200–
300mm3 at the start of treatment (Day 1). All animals were randomized
among treatment groups.

Drug treatment
Vandetanib (AstraZeneca, Macclesfield, UK) was administered by oral
gavage at 50mg/kg daily for 14 days, starting on Day 1. Vandetanib
dosing in this study was based on previous pharmacokinetic studies in
mouse models predicting relevance of this dosing to clinical drug exposure in human patients.16 CPT-11 was given at 15mg/kg intraperitoneally
on Days 1 and 3.

Tumor measurement
Tumors were synchronized to be approximately 250 mm3 at the start of
treatment (Day 1) and were measured four to five times per week, for
up to 6 weeks of follow-up, or until they reached 2,000 mm3. Tumor
size was determined by direct measurement with calipers and calculated
by the formula: (smallest diameter2 x widest diameter)/2. Tumors were
not allowed to grow beyond 2,000 mm3 in accordance with Institutional
Animal Care and Use Committee regulations.

In vivo tumor necrosis
Tumors were collected from animals on Day 14 after the start of treatment for fixation and staining with hematoxylin and eosin. The area of
necrosis was evaluated by image analysis and expressed as the percentage
of the total tumor area.

Radiation treatment

Statistical analysis

Irradiation was performed on anesthetized mice using X-rays generated
by a PanTak, 310 kVe X-ray machine, 0.25mm Cu+1mm Al added filtration, at 125cGy/min. Dosimetry was performed by an in-the-beam ionization chamber calibrated against a primary standard. Corrections were
made daily for humidity, temperature, and barometric pressure. Mice
were anesthetized with a combination of ketamine and acepromazine

Tumor growth was analyzed via mixed-effects regression, as previously
described. The method was used because it does not depend on an
arbitrary end point target tumor size, but uses the repeated tumor size
measurements obtained over the entire study period, while appropriately
handling unbalanced data (i.e., different number of measurements for
different animals) and the correlation of each animal’s measurements
over time. Mixed-effects regression yields generalizable parameters of
interest (e.g., average daily tumor growth rate, tumor doubling time), and
can investigate treatment interactions and nonlinear patterns of tumor
growth. The base-10 logarithm of tumor volume was modeled as a function of time and treatment. Linear or quadratic growth curves over time
were fitted to the log-transformed data, depending on growth patterns
in each treatment group. All statistical analyses were conducted in SAS
9.2 (SAS Institute Inc., Cary, NC, 1999–2001).

CPT-11
RT
Vandetanib
CPT-11
+ RT
CPT-11
+ vandetanib

Results

RT
+ vandetanib
CPT-11
+ RT
+ vandetanib

1

2

3

4

3

Tumor volume – 250 mm

5

6

7

8

9 10 11 12 13 14

Day

Control (untreated) group not shown

Figure 1. Summary of treatment groups. LoVo cells were implanted
subcutaneously into the right hind limbs of athymic NCR NUM
male mice. Mice were randomized into eight experimental groups
(11–16 animals per group). Vandetanib was administered at 50 mg/
kg daily orally for 14 days, starting on Day 1. CPT-11 was given at
15 mg/kg intraperitoneally on Days 1 and 3. Radiation was given
as three fractions (3x3 Gy) on Days 1, 2, and 3.
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at a concentration of 37.5mg/kg and 0.2mg/kg, respectively, to provide
25–30 min of sedation. Each mouse was confined in a lead casing with
its tumor-bearing leg extended through an opening on the side to allow
the tumor to be irradiated locally. Radiation was administered as three
daily fractions of 3 Gy each on Days 1, 2, and 3. On days when radiation
was administered with vandetanib or CPT-1, vandetanib and CPT-11
were given approximately 2h before radiation, with vandetanib preceding
CPT-11 administration.
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The experiment involved three different treatments (vandetanib, CPT-11,
and radiotherapy), as described above and summarized in Fig. 1. Data
were collected from a total of 104 animals in eight experimental groups
(11–16 animals per group) and are summarized in Fig. 2. Starting
tumor sizes were comparable across groups, with geometric means
ranging from 230 to 257mm3 (p = 0.771). All treatments were well
tolerated in the animals with no observable loss of body weight.
The three single-treatment groups (CPT-11, radiation, or vandetanib),
as well as the combination of CPT-11 with radiation (Fig. 2) were
fitted to log-transformed curves, whereas the three remaining groups
that received combination treatments involving vandetanib showed
a significantly nonlinear tumor growth and were fitted to quadratic curves.
Figure 3 shows the measured geometric mean tumor size graphically over
time. Table 1 shows the corresponding calculated tumor growth parameters
(daily tumor growth rate and tumor doubling time). Table 2 shows p values
for group comparisons at 7, 14, and 21 days after start of treatment.
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Figure 2. Tumor growth curves in LoVo xenografts treated with vandetanib, irinotecan (CPT-11), and/or radiation. Individual mouse data are
shown for eight treatment groups (11–16 animals per group), along with fitted group curves. Vandetanib was administered at 50 mg/kg daily
orally for 14 days, starting on Day 1. CPT-11 was given at 15 mg/kg intraperitoneally on Days 1 and 3. Radiation was given as three fractions
(3x3 Gy) on Days 1, 2, and 3.
The control group had an estimated average daily tumor growth rate
of 9.9%, corresponding to an average tumor doubling time of about
7 days (Table 1). All three single treatments resulted in a significant
inhibition of tumor growth, compared with the control group (average
daily tumor growth rates: CPT-11: 7.1%, p = 0.015; radiation: 5.6%,
p = 0.001; vandetanib: 5.0%, p = 0.001). Vandetanib inhibited tumor
growth significantly more than CPT-11 (p = 0.043), but not radiation
(p = 0.514); radiation and CPT-11 were not significantly different
(p = 0.139). The combination of CPT-11 with radiation produced a
daily tumor growth rate of 5.1%, which was significantly lower than
CPT-11 alone (p = 0.015) but comparable to radiation alone (p = 0.560).
There was no significant (additive) interaction between CPT-11 and
radiation (p = 0.105).

The remaining three groups that received treatment combinations
involving vandetanib (with either CPT-11 or radiation, or with both
CPT-11 and radiation), showed significant treatment interactions
(p = 0.001 for the interaction between vandetanib and CPT-11 and
between vandetanib and radiation) and nonlinear tumor growth patterns.
Compared with single-treatment groups, growth was significantly
delayed (and, in the triple-treatment combination, tumor volume
actually decreased) early on, but progressively accelerated later, although
it never exceeded that of the untreated controls (Fig. 3). Because of the
nonlinearity of tumor growth in these groups, tumor growth parameters
are not constant over time and comparisons depend on the time point
referenced. Table 2 shows p values for Days 7, 14, and 21.
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than for either radiation alone or vandetanib alone (p = 0.005 and
0.019, respectively). After 14 days, the tumor growth rate in the
combination group had accelerated to 3.4% and was only marginally
lower than for radiation alone and comparable to that for vandetanib
alone (p=0.080 and 0.212, respectively). By the third and fourth
weeks, tumor growth had become similar to that seen in the singletreatment groups (Fig. 3, Table 1).

Tumor Volume (mm3)

10,000

1,000

Despite delaying tumor growth in the initial weeks, the treatment
combinations induced only modest levels of tumor necrosis (10–20%),
with no significant differences between treatment groups (Fig. 4).

CTR
CPT-11
RT
VAN
CPT-11+RT
VAN+CPT-11
VAN+RT
VAN+CPT-11+RT

100

The pattern of tumor growth in the group that received the tripletreatment combination reflected both the interaction between
vandetanib and CPT-11 and that between vandetanib and radiation
(as mentioned previously). Thus, during the first week, instead of
the delayed tumor growth seen in the two-treatment combinations,
tumor volume in the triple-treatment combination actually decreased
(p = 0.001 vs. vandetanib plus CPT-11, and 0.052 vs. vandetanib plus
radiation). After that time, similar to the two-treatment combinations
that involved vandetanib, tumor growth started accelerating. By the end
of the third week, tumor growth in the triple-treatment combination
group was similar to that in the two-treatment combination groups
involving vandetanib, and by the fourth week, it was similar to that in the
single-treatment groups.

10
0

7

14

21

28

35

42

Time (days)
Figure 3. Estimated geometric mean tumor volume over time in
LoVo xenografts treated with vandetanib, CPT-11, and/or radiation.
Vandetanib was administered at 50 mg/kg daily orally for 14 days,
starting on Day 1. CPT-11 was given at 15 mg/kg intraperitoneally
on Days 1 and 3. Radiation was given as three fractions (3x3 Gy)
on Days 1, 2, and 3.

Discussion
During the first week of treatment, animals receiving the combination
of vandetanib with CPT-11 had average daily tumor growth rate of
less than 3.5%, significantly lower than CPT-11 alone and marginally
so compared with vandetanib alone (p = 0.001 and 0.058, respectively,
after 7 days). By the end of the 2-week vandetanib treatment, the
tumor growth rate in the combination group (4.6%) was still significantly
lower than for CPT-11 alone (p = 0.015) but comparable to that for
vandetanib alone (p = 0.682). By the third and fourth weeks, tumor
growth had reached levels similar to those seen in the single-treatment
groups (Fig. 3, Table 1).
The combination of vandetanib with radiation resulted in a similar
pattern of nonlinear tumor growth inhibition. After the first 7 days,
the average daily tumor growth rate of 2.1% was significantly lower

Relatively little is known about the antitumor effects of combining
cytotoxic drugs, radiotherapy, and novel targeted therapies that specifically
interfere with signaling pathways controlling cancer proliferation, angiogenesis, and survival. In the present study, vandetanib, a potent inhibitor
of both VEGFR and EGFR signaling, was combined with CPT-11 or radiation, to determine if greater anti-colorectal tumor activity can be obtained.
This study demonstrated that all three single treatments (vandetanib,
CPT-11, and radiation) significantly slowed LoVo colorectal tumor
growth. Previous studies with single-agent vandetanib demonstrated
that chronic oral administration reduced tumor vascularity and tumor
growth in a variety of xenograft models, including CRC.7, 17 In the clinic,
the safety and tolerability of vandetanib has been demonstrated in
patients with advanced colorectal cancer as well as other solid tumors.18

Table 1. Estimates of the average daily tumor growth rate and average tumor doubling time, by treatment group

__________
1

%Δ(T2x)

__________ __________ __________ __________ __________
7

14

21

28

35

%Δ(T2x)

%Δ(T2x)

%Δ(T2x)

%Δ(T2x)

%Δ(T2x)

8.9 (8.2)

CTR

9.9 (7.4)

CPT-11

7.1 (10.2)

RT

5.6 (12.7)

VAN

5.0 (14.3)

CPT-11 + RT

5.1 (13.9)

VAN + CPT-11
VAN + RT
VAN + CPT-11 + RT

†

Time (days)

0.9 (75.4)

1.9 (37.1)

3.2 (22.2)

4.6 (15.5)

6.0 (11.9)

7.4 (9.7)

2.1 (33.4)

3.4 (20.9)

4.7 (15.2)

6.0 (11.9)

7.3 (9.8)

0.0 N/A

2.4 (28.7)

4.9 (14.5)

7.4 (9.7)

-2.1 N/A

%Δ: estimated average daily rate of increase/decrease of tumor volume (%).
T2x: estimated average doubling time of tumor volume (in days).
N/A: not applicable (tumor shrinks or is stable).

CTR, CPT-11, RT, VAN, and CPT-11+VAN groups had log-linear tumor growth, so their parameters were constant over time. The remaining
groups did not have log-linear tumor growth, so their parameters were changing over time.
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9.9 (7.3)

Radiotherapy

Table 2. P-values for comparisons of treatment groups, on days 7, 14, and 21, after the start of treatment
Day 7

Day 14

Day 21

CTR
CPT-11

0.015 vs. CTR; 0.139 vs. RT; 0.043 vs. VAN

RT

0.001 vs. CTR; 0.139 vs. CPT-11; 0.514 vs. VAN

VAN

0.001 vs. CTR; 0.043 vs. CPT-11; 0.514 vs. RT

CPT-11 + RT
VAN + CPT-11
VAN + RT
VAN + CPT-11 + RT

0.001 vs. CPT-11; 0.560 vs. RT
0.001 vs. CPT-11; 0.058 vs. VAN

0.015 vs. CPT-11; 0.682 vs. VAN

0.005 vs. RT; 0.019 vs. VAN

0.080 vs. RT; 0.212 vs. VAN

0.346 vs. CPT-11; 0.395 vs. VAN
0.496 vs. RT; 0.830 vs. VAN

0.001 vs. CPT-11; 0.001 vs. RT;
0.001 vs. VAN
0.001 vs. CPT-11+RT; 0.001 vs.
VAN+CPT-11; 0.052 vs.
VAN+RT

0.001 vs. CPT-11; 0.001 vs. RT;
0.007 vs. VAN
0.001 vs. CPT-11+RT; 0.017 vs.
VAN+CPT-11; 0.407 vs.
VAN+RT

0.011 vs. CPT-11; 0.366 vs. RT;
0.917 vs. VAN
0.766 vs. CPT-11+RT; 0.294 vs.
VAN+CPT-11; 0.868 vs.
VAN+RT

CTR, CPT-11, RT, VAN, and CPT-11+VAN groups had log-linear tumor growth and therefore comparisons do not depend on time.
The remaining groups did not have log-linear tumor growth and therefore comparisons that involve them depend on time.

Vandetanib induced manageable normal tissue toxicities related to
inhibition of EGFR and VEGFR signaling such as diarrhea, rash, and
hypertension.19, 20 The effect of combining radiation and vandetanib on
normal tissue is currently unknown, however it has been shown in both
preclinical and clinical trials that use of VEGF inhibitors with radiation
may result in higher rates of normal tissue toxicity such as induction
of thrombosis, hemorrhage, and bowel toxicities.21–23 In contrast, it was
postulated that combination of radiotherapy with inhibitors of angiogenesis may actually decrease these risks because radiotherapy has been
used to prevent hemorrhage.24 Overall, the investigation of agents such
as vandetanib in combination with radiation in normal tissue is lacking,
and thus will be a major focus in the future.
As previously discussed, single-agent vandetanib has dual tyrosine
kinase inhibitory activity against VEGFR-2 and EGFR, which allows
it to target two key pathways responsible for tumor growth (i.e., tumor

angiogenic signaling, tumor cell proliferation). It has been speculated
that dual suppression may be critical for sustained suppression of tumor
growth, especially because the EGFR and VEGFR pathways are linked
and exhibit cross-talk.25 In addition, vandetanib can also enhance the
antiproliferative activity of selective EGFR inhibitors such as cetuximab,
thereby potentiating suppression of EGFR signaling.17
The present study confirmed that vandetanib, chronically administered
over 2 weeks, slowed tumor growth in a colorectal tumor model, and,
under the dosing conditions of this study, slowed tumor growth to
a greater extent than CPT-11 alone and to a similar level to radiation
alone. Moreover, vandetanib significantly increased the antitumor effects
of CPT-11 and radiation, when given in combination with either of these
treatments. In particular, these treatment combinations resulted in a slow
tumor growth rate during the 2 weeks of vandetanib administration. These
results confirm an earlier study by Troiani et al.,26 in which vandetanib

Figure 4. Hematoxylin and eosin stained
sections of LoVo colorectal xenografts. All
tumors were collected from animals on Day
14 after the start of treatment. Areas of
necrosis are denoted by nec. Magnification
20x. (a) Control (untreated) tumor, showing
2% necrosis. (b) Tumor from animal after
administration of last dose of vandetanib,
showing 15% necrosis. (c) Tumor from
animal after administration of CPT-11 and
RT, showing 20% necrosis. (d) Tumor from
animal after administration of vandetanib and
CPT-11, showing 10% necrosis.
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(25mg/kg/day) administered in combination with CPT-11 exhibited
high antitumor activity in HT29-tumor–bearing nude mice. Troiani et al.
showed a correlation between this dosing schedule and enhanced EGFR
and VEGFR signal inhibition.
In the present study, the triple combination of vandetanib, CPT-11, and
radiation produced the most marked improvement in response in the
LoVo- tumor–bearing mice. The triple treatment produced a measurable
shrinkage of tumors during the first week of treatment. The combination of
vandetanib, chemotherapy (gemcitabine), and radiation has also been
previously shown to significantly inhibit tumor progression in a pancreatic
tumor model.27 Importantly, the present study also investigated the
kinetics of tumor growth, both during and after a course of treatment. It was
demonstrated that the addition of vandetanib significantly enhanced
the initial antitumor effect of chemo-radiation. However, when vandetanib
treatment ended, tumor growth returned to near control (untreated)
levels. Therefore, these data support the rationale of adding an antivascular
agent to cytotoxic therapies and provide valuable information for the
design of therapeutic protocols.
The precise mechanisms leading to initial tumor regression with the
combined therapies in this study are not known. Analysis of interactions
between cytotoxic agents and vandetanib is complex, given that both
the tumor cells and the tumor microenvironment are affected. In this
connection, radiation can kill not only tumor cells but also endothelial
cells of the tumor vasculature, thereby affecting the radiosensitivity of
the tumor (28, 29). In addition, cytotoxic agents have mechanisms of cell
killing that are different from the targeted agent. Both radiation and CPT-11
kill cells through DNA damage. Both chemotherapy and radiation can
also alter cellular signaling pathways by inducing EGFR phosphorylation
and through the growth factor signaling pathway, contribute to tumor
cell proliferation and survival.30–32 Preclinical studies have also shown that
cytotoxic therapy alone, such as radiation, can result in intensification
of angiogenic processes.33 After cytotoxic treatment, upregulation of
vascular growth factors and their receptors occurs, which contributes
to tumor recurrence and progression.34 Direct upregulation of VEGF
after irradiation of various cancer cell lines has been reported.35 Radiation also induces transient tumor hypoxia which results in upregulation
of hypoxia inducible factor-1 (HIF-1) which can stimulate VEGF and
VEGFR-2 expression. Therefore, simultaneous inhibition of both VEGFR
and EGFR signaling through chronic administration of vandetanib in
combination with cytotoxic therapy is expected to suppress the upsurge
in pro-proliferative and angiogenic signaling resulting from CPT-11 and
radiation-induced EGFR and VEGF. This suppression will thereby lead
to inhibition of vascular protective mechanisms and growth factor
mechanisms contributing to tumor regrowth.
The increased tumor growth that was seen in this study after discontinuation of vandetanib suggests that inhibition of angiogenic and proproliferative signaling is readily reversed. The current observations are in
agreement with a number of both preclinical and clinical studies showing
that tumors can adapt to anti-angiogenic treatment by undergoing
‘‘evasive resistance’’ to angiogenesis inhibitors.36 Mechanisms of resistance
include upregulation of alternative proangiogenic signaling pathways as
well as recruitment of bone marrow–derived proangiogenic cells.37, 38
In addition, administration of vandetanib itself has been observed to
increase VEGF production in certain cancer cell lines as well as in tumor
xenografts,39, 40 thereby suggesting an additional contributing mechanism
to tumor relapse. More studies will be needed to determine whether additional angiogenic pathways may be induced by triple modality treatment.
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Conclusions
The results of this study provide a scientific rationale for testing the
combination of vandetanib, CPT-11, and radiation in patients with
CRC. Although the best schedule and sequencing for this triple modality
treatment has yet to be determined, the tumor growth delay kinetics
observed in this study suggest that improvement in colorectal
tumor response can be obtained by concurrent and sustained postsequencing of vandetanib with cytotoxic therapy, keeping in mind
that prolonged chronic administration of the receptor tyrosine kinase
inhibitors may lead to the development of resistance and the requirement
for additional therapeutic agents as seen with other targeted agents,
such as imatinib and gefitinib.41, 42
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Abstract
Background: Locoregional recurrence (LRR) is an important factor after pancreaticoduodenectomy (PD) for pancreatic cancer. IORT administered to the resection bed may improve local
tumor control.
Methods: We performed a retrospective analysis of patients who underwent PD at Thomas
Jefferson University Hospital (TJUH) between 1995 and 2005 to identify patients who underwent
resection with and without intraoperative radiation therapy (IORT). Data collected included age,
gender, complications, margin status, stage, survival, and recurrence. Unadjusted analyses of
the IORT and non-IORT groups were performed using Fisher’s chi-square method for discrete
variables and Wilcoxon Rank Sum test for continuous variables. To account for biases in patient
selection for IORT, a propensity score was calculated for each patient and adjusted statistical
analyses were performed for survival and recurrence outcomes.
Results: Between January 1995 and November 2005, 122 patients underwent PD for perimpullary
tumors, including 99 pancreatic cancers. Of this group, 37 patients were treated with IORT, and
there was adequate follow-up information for a group of 46 patients who underwent PD without
IORT. The IORT group contained a higher percentage of Stage IIB or higher tumors (65%)
than in the non-IORT group (39.1%), though differences in stage did not reach significance
(p = 0.16). There was a non-significant decrease in the rate of LRR in patients who had IORT (39%
non-IORT vs. 23% IORT, p = 0.19). The median survival time of patients who received IORT was
19.2 months, which was not significantly different than patients managed without IORT, 21.0
months (p=0.78). In the propensity analyses, IORT did not significantly influence survival or
recurrence after PD.
Conclusions: IORT can be safely added to management approaches for resectable pancreatic
cancer, with acceptable morbidity and mortality. IORT did not improve loco-regional control and
did not alter survival for patients with resected pancreatic cancer. IORT is an optional component
of adjuvant chemoradiation for pancreatic cancer. In the future, IORT may be combined with
novel therapeutic agents in the setting of a clinical trial in order to attempt to improve outcomes
for patients with pancreatic cancer.
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Surgical resection is an essential component
in the therapeutic approach to patients with
localized pancreatic cancer. Despite refinements in surgical technique, local and distant
recurrences are common. Long-term survival
rates are low for patients with resectable
tumors, with 15-20% 5-year survival reported
among patients who undergo pancreaticoduodenectomy (PD) alone.1, 2 In a review of
resection margins of 72 patients who underwent PD, Willett et al. detected a positive margin in 51% of cases; this factor was associated
with inferior survival and local control when
compared with those patients with negative
surgical margins.2 Although there is controversy
regarding the appropriate components of
adjuvant management of resected pancreatic
cancer,3-7 outcomes achieved after surgery
alone continue to be poor; therefore, the need
remains for adjuvant therapy to improve local
control and survival.3-8 In the United States,
adjuvant chemoradiotherapy (CRT) is performed
as part of the standard therapeutic paradigm,
based on the recurrence patterns of pancreatic
cancer after surgery.8, 9
Intraoperative radiation therapy (IORT), the
delivery of a single, large dose of irradiation at
the time of surgery, was developed in order
to administer higher doses of irradiation while
displacing or shielding adjacent normal tissue
structures from radiation exposure .10 In pancreatic
cancer, IORT has been offered for unresectable tumors to provide local tumor control
and palliation of pain,11-16 and for resectable
tumors in an effort to improve local control
and survival after PD.11-19 Although a definitive
survival benefit has not been observed,
improvement of local control by IORT at the
time of PD for resectable pancreatic cancer is
supported by retrospective data, as well as by a
prospective, randomized trial conducted at the
National Cancer Institute (NCI).19-21

Studies

At our institution, IORT has been offered since 1986 in a dedicated
operating suite located in the radiotherapy department for patients with
either resectable or unresectable pancreatic cancer. IORT was considered for
all patients undergoing PD at our institution until 1998. Since then, IORT
has been reserved for patients with larger tumors with higher risk of
positive margins, as visualized by the surgeon on preoperative imaging.
Prior reports from our institution have described outcomes of patients
who received IORT for resectable and unresectable pancreatic cancer
prior to 1995.13, 22 The current study evaluates outcomes for patients who
received treatment for resectable pancreatic cancer from 1995 to 2005.
As a result of physician bias for the use of IORT in more advancedstage pancreatic cancer at our institution, it was not possible to identify
a comparative group of patients for use in a matched pair analysis.
Therefore, in order to account for the biases inherent in the nonrandom
treatment assignment for patients in the current study, analyses of
survival and recurrence were adjusted using propensity scoring.23 In this
way, we attempted to minimize the influence of confounding patientand tumor-related variables in order to assess the contribution of
IORT to local tumor control and survival of patients with localized,
resectable pancreatic cancer treated at our institution.

Materials & Methods
A prospective tumor registry database was searched to identify all
patients who underwent PD at Thomas Jefferson University during
1995-2005. The study was performed with approval of the institutional
review board at Thomas Jefferson University. These patients were
further divided into those who did and did not receive IORT. We
collected data regarding age, gender, margin status, stage, survival and
recurrence. Loco-regional recurrence (LRR) was defined as recurrence
within the tumor bed or regional lymph nodes. Systemic recurrence
(SR) consisted of recurrence in the liver, peritoneum, lungs, bone, or
other distant site. Overall survival (OS) and time to LRR were measured
from the date of surgery. Given the institutional bias towards IORT for
larger tumors during much of the study period, a difference between
treatment groups was anticipated in the statistical analysis. A propensity
score, a statistical method to adjust for nonrandom treatment decisions
in observational studies, was also calculated for each patient using a
logistic regression model.23

Treatment Policy
All patients were treated according to institutional treatment policies
during 1995-2005. As a general rule, IORT was considered for all
patients prior to 1998 and subsequently for patients with larger tumors
based on review of preoperative imaging by the attending surgeon. For
these patients, surgery was performed in an operating room located
in the radiation oncology department, an arrangement selected to
facilitate IORT delivery. IORT was delivered using 6-15 MeV electrons
and cone sizes selected in order to deliver a dose of 10-20 Gy to a field
encompassing the pancreatic tumor bed within the 90% isodose line.
Regional lymph nodes were not included in the target volume for
most cases. The cone size, treatment set-up, and immobilization were
selected in order to treat the target volume while minimizing exposure
of adjacent normal tissue structures. The standard dose, 15 Gy, was
reduced to 10 Gy for either large treatment volumes or margins that
were clearly negative. For larger tumors, 20 Gy was often prescribed.
In cases where adjuvant external beam radiation therapy (RT) was
also delivered, a dose of 45-50.4 Gy was prescribed using a conformal,
four-field radiation technique.

Statistical Analysis
Simple descriptive statistics were generated, and unadjusted associations
with IORT were determined using Fisher’s Chi Square test for categorical
variables and using the Wilcoxon rank sum test for continuous variables.
The propensity score, which was calculated for all patients included in
the analysis using a logistic regression model, included resection status,
AJCC Stage, differentiation, age, race, and sex. Propensity scores were
incorporated as a categorical variable in the statistical analyses based
on quartiles. The association of IORT with the primary outcome of
survival was determined using a Cox proportional hazards model.
The Cox proportional hazards model included IORT, the propensity
score (by quartile), adjuvant chemotherapy, and adjuvant radiotherapy.
Association of IORT with the secondary outcomes of any recurrence,
loco-regional recurrence, and systemic recurrence was determined using
logistic regression models. Included in the logistic regression models for
adjusted analyses of recurrence were IORT, the propensity score (by
quartile), adjuvant chemotherapy, and adjuvant radiotherapy.

Results
From January 1995 to November 2005, 122 patients underwent PD for
periampullary tumors, including 99 pancreatic cancers. We identified
37 patients with pancreatic cancer who were treated with IORT. Among
the remaining 62 patients with pancreatic cancer treated without IORT,
adequate follow-up data could be obtained for 46 patients, who comprised
the non-IORT group used in the statistical analyses. The median patient
age in the IORT group was 64 years (inter-quartile range, 55-70 years); in
the non-IORT group, the median age was 67 years (inter-quartile range,
59-74 years). The IORT group demonstrated non-significant trends
toward more advanced stage tumors (p=0.16) and a higher rate of positive
margins (p=0.26). A higher proportion of patients received adjuvant
chemotherapy after PD with IORT than after PD alone (p=0.05) (Table 1).
There were 2 perioperative deaths in the IORT group (5.4%) and none in
the non-IORT group (p=0.20). Rates of perioperative complications were
similar, 46% in the IORT group versus 40% in the non-IORT group. The
median follow-up among surviving patients was 21 months.

Recurrence and Survival
Recurrence data were available for 80% of all patients, including 30 IORT
patients (81%) and 36 non-IORT patients (78%). Rates of loco-regional
recurrence (LRR) (Figure 1) or any recurrence (Figure 2) were not
significantly different between the IORT and non-IORT groups. Among
non-IORT patients, there was loco-regional recurrence (LRR) in 39%,
systemic recurrence (SR) in 50%, and any recurrence in 69%. In the
IORT group, LRR in 23%, SR in 57% of patients, with, and recurrence
was observed in 67% (Table 2). Liver metastases were the most common
form of SR. LRR in the absence of SR was observed in 2 patients (7%)
in the IORT group and in 7 patients in the non-IORT group (19%). LRR
was not significantly different between the IORT and non-IORT groups
(p=0.20). The median survival time of patients undergoing IORT was
19.2 months, which was not significantly different than patients managed without IORT, 21.0 months (p=0.49) (Figure 3).

Propensity Score Analysis
In the adjusted, propensity score analysis of the association of IORT
with survival, IORT was not associated with significant improvement of
survival time (Table 3). The Cox regression model for survival included
IORT status with propensity score (by quartile), as well as adjuvant RT and
chemotherapy. The propensity score-adjusted analyses of the association
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Table 1. Tumor- and treatment-related characteristics for
37 IORT patients and 46 non-IORT patients with resected
pancreatic cancer.
PD + IORT
[n (%)]

PD (No IORT)
[n (%)]

I

7 (19)

16 (35)

IIA

6 (16)

12 (26)

≥IIB

24 (65)

18 (39)

Factor

Stage

Margin Status

RO

21 (57)

32 (70)

R1/R2

16 (43)

14 (30)

7 (19)

8 (18)

Moderate

21 (58)

25 (56)

Poor

8 (22)

12 (27)

Adjuvant
Chemotherapy
(n=79)

Yes

26 (84)

27 (63)

No

5 (16)

16 (37)

Adjuvant EBRT
(n=75)

Yes

23 (74)

29 (66)

No

8 (26)

15 (34)

(n=81)

0.16

PD + IORT
[n (%)]

PD (No-IORT)
[n (%)]

7 (23)

14 (39)

Locoregional

0.26

Tumor Bed

6 (20)

8 (22)

Lymph Node

4 (13)

10 (28)

Locoregional-Only
Liver

0.91

0.05

0.44

of IORT with LRR, with SR, and with any recurrence were conducted
using logistic regression models (Table 4). After adjusting for propensity
score quartile and for adjuvant therapies, IORT did not influence recurrence rates after PD for pancreatic cancer. A non-significant trend towards
higher rates of any recurrence was noted for propensity scores in the third
(OR 9.66, p = 0.14) or fourth quartile (OR 9.64, p = 0.15).

Discussion
Local control was not significantly different between the two groups,
IORT and non-IORT, evaluated in the current series. Although the
current study is limited by its retrospective design and institution bias
towards treating more advanced tumors with IORT, an attempt was

2 (7)

7 (19)

17 (57)

18 (50)

11 (37)

11 (31)

Lung/Pleura

4 (13)

7 (19)

Systemic-Only

14 (47)

11 (31)

made to account for nonrandom allocation of patients into the IORT
and non-IORT groups by using propensity score values in adjusted
statistical analyses of the association of IORT with survival and recurrence.
Adjuvant chemotherapy was administered to more patients in the
IORT group. Although information concerning decision-making was
not available, the increased rate of chemotherapy may be related to the
presence of more advanced tumors in the IORT group. Despite the trends
toward more advanced-stage tumors and positive resection margins in
the IORT group, similar local control rates were observed.
The disparities in stage and margin status in the current study may have
obscured any potential local control benefit of IORT, as these factors have
been reported to negatively influence survival for patients with resected
pancreatic cancer.24, 25 Prior retrospective, single-institution reports
suggest that IORT improves local control after PD by approximately
30%.19, 21 In this study, LRR was 50% less in the IORT group. In the
prospective, randomized trial conducted at the NCI, local control
improved from 0% to 33% with the addition of IORT.20 In a recent series
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Figure 1. Kaplan-Meier plot of locoregional failure for patients
treated with (solid line) and without (dashed line) IORT (p = 0.20).

20

Site of First Recurrence

Systemic

Well

Grade

p value

Table 2. Location of first recurrence. Thirty patients in the IORT
group and 36 patients in the non-IORT group were included in
the recurrence analysis, based on availability
of data to determine site of recurrence.
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Figure 2. Kaplan-Meier plot of recurrence (any site) for patients
treated with (solid line) and without (dashed line) IORT (p = 1.0).

Studies

Table 2. Location of first recurrence. Thirty patients in
the IORT group and 36 patients in the non-IORT group were
included in the recurrence analysis, based on availability
of data to determine site of recurrence.
Site of First Recurrence

Table 4. Logistic regression models of the association of IORT,
propensity score, and other factors, with the outcomes of any
recurrence, locoregional occurrence, and systemic recurrence.
Odds Ratio

PD + IORT
[n (%)]

PD (No-IORT)
[n (%)]

7 (23)

14 (39)

Locoregional
Tumor Bed

6 (20)

8 (22)

Lymph Node

4 (13)

10 (28)

Locoregional-Only
Systemic

2 (7)

7 (19)

17 (57)

18 (50)

Liver

11 (37)

11 (31)

Lung/Pleura

4 (13)

7 (19)

Systemic-Only

14 (47)

11 (31)

95% CI

p

Any Recurrence

IORT

0.77

(0.19, 5.20)

0.72

Adjuvant Chemotherapy

1.69

(0.15, 19.29)

0.67

Adjuvant Radiotherapy

1.11

(0.11, 11.68)

0.93

Propensity Score (vs. 1st Quartile)
2nd Quartile

1.22

(0.33, 4.52)

0.76

3rd Quartile

9.66

(0.47, 197.40)

0.14

4th Quartile

9.64

(0.46, 203.31)

0.15

IORT

0.41

(0.10, 10.30)

0.23

Adjuvant Chemotherapy

0.49

(0.02, 11.37)

0.65

Adjuvant Radiotherapy

1.74

(0.86, 35.51)

0.72

Locoregional Recurrence

from the City of Hope National Medical Center, isolated local recurrences were reduced from 33% to 5% with the addition of IORT, which
is comparable to the rate of isolated LRR in the current report (7%).24
Reni et al. reported a similar alteration of recurrence patterns, with 15%
local-only recurrences with IORT versus 33% without IORT.26 The
cumulative evidence, including one prospective randomized trial and a
few prospective studies, supports a local control benefit for IORT in
resectable pancreatic cancer. An improvement in local control has not
been shown to translate into a clinical benefit in survival outcomes,
including in this study. Although a propensity score analysis was
performed in the current study to evaluate the influence of IORT on
recurrence rates after PD, the limited size of the patient population may
have restricted our ability to detect a significant positive effect.
The survival rates were not different between the IORT and non-IORT
groups in the current series, which is consistent with the results of
the prospective NCI study.20 Given the propensity of pancreatic cancer
towards distant metastatic recurrence, it is not surprising that a measurable
increase in local control did not produce a corresponding improvement
of survival.27 Although some authors report a survival benefit
from IORT for resectable pancreatic tumors at their institutions, the
literature does not consistently support this claim, and detection of a

Table 3. Cox proportional survival hazard model for
the association of IORT, propensity score, and other
factors with survival time in months.
Estimate

Standard
Error

Chi-Square

Hazard
Ratio

p

IORT

-0.34

0.35

0.94

0.71

0.33

Adjuvant
Chemotherapy

0.51

0.73

0.48

1.66

0.49

Adjuvant
Radiotherapy

-1.05

0.68

2.39

0.35

0.12

Propensity Score (vs. 1st Quartile)
2nd Quartile

-0.68

0.45

2.35

0.50

0.13

3rd Quartile

0.55

0.49

1.26

1.73

0.26

4th Quartile

0.58

0.47

1.56

1.79

0.21

Propensity Score (vs. 1st Quartile)
2nd Quartile

0.39

(0.02, 7.47)

3rd Quartile

5.13

(0.73, 36.03)

0.53
0.10

4th Quartile

3.32

(0.46, 23.93)

0.23

0.99

(0.28, 3.52)

0.99

Systemic Recurrence

IORT
Adjuvant Chemotherapy

0.40

(0.03, 6.42)

0.52

Adjuvant Radiotherapy

1.30

(0.10, 16.96)

0.84

Propensity Score (vs. 1st Quartile)
2nd Quartile

1.11

(0.23, 5.40)

0. 90

3rd Quartile

0.91

(0.16, 5.13)

0.91

4th Quartile

0.59

(0.10, 3.50)

0.56

potential small survival benefit would require a large trial.19, 22, 24, 26, 28, 29
Regardless of the absence of improved survival, the problem of
locoregional control does leave open a place for radiation therapy after
PD, and IORT is an effective technique to boost radiation dose around
the resection bed while displacing sensitive adjacent organs.8, 10, 17, 30 A
recent analysis of the Surveillance, Epidemiology, and End Results database revealed a survival benefit to the addition of adjuvant radiotherapy
after PD, and radiation therapy remains an important component of
adjuvant strategies in the United States.25 Results recently published
from the Radiation Therapy Oncology Group (RTOG) trial 9704, the
first cooperative group study to require prospective quality assurance of
radiotherapy, suggest a benefit to the addition of gemcitabine to adjuvant
CRT after PD. The rates of first relapse in local and regional sites in the
experimental arm of RTOG 9704 were 23% and 7%, respectively..31
Importantly, the addition of IORT after PD did not increase perioperative complication rates significantly in the current series, which is
consistent with the earlier experience from our institution.22 Although
late complications have been reported after IORT for pancreatic cancer,
our results and other reports suggest that IORT may be delivered
safely in combination with surgical resection.24, 26, 28, 32, 33-37 Selection of
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Abstract
Flexible needle steering has aroused a lot of research interest in recent years. It has the potential to
correct targeting errors, which may be caused by needle bending, tissue deformation, or error in
insertion angle. In addition, control and planning based on a steering model can guide the needle
to some areas that are currently not amenable to needles because of obstacles, such as bone or
sensitive tissues. Thus, there is a clear motivation for needle steering. In this paper, a spring–beam–
damper model is proposed to describe the dynamics during the needle–tissue contact procedure.
Considering tissue inhomogeneity, depth-varying mean parameters are proposed to calculate the
spring and damper effects. Local polynomial approximations in finite depth segments are adopted
to estimate the unknown depth-varying mean parameters. Based on this approach, an online
parameter estimator has been designed using the modified least-square method with a forgetting
factor. Some preliminary experiments have been carried out to verify the steering model with the
online parameter estimator. The details are given in this paper. Finally, conclusions and future
studies are given at the end.
Index Terms: Depth-varying mean parameter, needle steering modeling,
percutaneous surgery, spring–beam–damper model.

I. Background
Medical procedures, such as brachytherapy, biopsies, and treatment injections, require inserting a
needle to a specific target location inside the human body to implant a radioactive seed, extract a
tissue sample, or inject a drug. Precise needle placement is very important. Poor placement may
cause tissue damage, misdiagnosis, poor dosimetry, and tumor seeding. Unfortunately, precise
needle placement is hard to achieve in real practice. Errors caused by the target movement and
needle deflection have been observed for a long time.1-4 Yet to date, there are few effective physically
based needle steering systems existing for correcting the targeting error automatically when it
is observed. It is interesting to note that during clinic practice, some surgeons make use of a
combination of lateral, twisting, and inserting motions of the needle under visual feedback from
imaging systems, such as ultrasound, to correct the targeting errors. Surgeons accomplish this
from experience, making it difficult to teach and limiting the accuracy to that of human hand/
eye coordination.
Flexible needle steering was first addressed by DiMaio et al.5 using a finite-element model. His
model was later extended by other researchers to 3-D models.6, 7 In the Medical Image Computing
and Computer-Assisted Intervention Conference 2005, Daniel Glozman and Moshe Shoham8
presented a simplified virtual spring model for the needle insertion procedure. Modeling of a
flexible needle was based on the assumption of quasistatic motion and a third-order polynomial
was used to calculate the displacement of each element. Compromise had to be made between the
computational efficiency and the model accuracy.
Needle steering making use of the needle bending has also been explored in the past few years.
Some researchers have generated needle bending using different strategies, such as incorporating
a prebent stylus inside a straight canula,9 or a telescoping double canula, where the internal
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canula is prebent.10 Other researchers showed
that needles with bevel tips bend more
than symmetric-tip needles.11 Making use
of this effect, thin highly flexible bevel-tip
needles using Nitinol were developed, and a
nonholonomic model was built accordingly
for steering flexible bevel-tip needles in
rigid tissues.12 The nonholonomic model, a
generalization of a 3-D bicycle model, was
experimentally validated using a very stiff tissue
phantom. Recent advances in nonholonomic
path planning include stochastic model-based
motion planning to compensate for noise
bias,13 probabilistic models of dead-reckoning
error in nonholonomic robots,14 a diffusionbased motion planning to search for a feasible
path in full 3-D space, and motion planning
under Markov motion uncertainty using
dynamic programming to search for a feasible
route while avoiding obstacles.15
In this paper, a needle steering model is
proposed for flexible needle steering purpose.
A spring–beam–damper model is adopted
to model the dynamics between the lateral
needlebased force and the corresponding
lateral needle tip movement with consideration
of the needle flexibility and tissue deformation.
Considering the tissue inhomogeneity, depthvarying mean parameters are proposed to
calculate the spring and damper effects. Local
polynomial approximations in finite-depth
segments are adopted to estimate the unknown
depth-varying mean parameters. Unlike the
models proposed in5 and,8 this model takes into
consideration not only the viscoelastic tissue
reactions but also the tissue inhomogeneity.
In the literature, the spring–damper model
has been adopted by many research groups
in studying tissue deformation.16–18 But how
the coupled interaction of the instrument
and soft tissue is and how to control the
instrument while in collision with such an
environment have received little attention.
Some researchers studied the collision of
the flexible link with the environment in the
application of grinding or surface turning
operation.19,20 They modeled the environment
as a simple spring–damper system, which was
assumed to be stationary and was arbitrarily
placed along the trajectory such that the beam
would only make contact with it at the tip. In
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Needle position
without deflection

Needle body trajectory

Under the aforesaid assumptions, the system dynamic equation can be
derived using Hamilton’s principle as follows:

where T is the kinetic energy, V is the potential energy, and Wnc is the
work done by nonconservative forces.

Tip trajectory

Figure 1. Mechanism of the needle insertion procedure.

the application of needle steering, the flexible instrument interacts with
the environment with changing force along the needle body from time
to time. The situation is much more complicated compared with the
point contact.
Based on the proposed model, an online parameter estimator has been
designed using the modified least-square method with a forgetting
factor. Preliminary experiments have been carried out to verify the
steering model with the online parameter estimator. Results have shown
its effectiveness. Finally, conclusions and future studies are given at the end.

II. Needle Lateral Steering Force Modeling
And Analysis

A local coordinate system is introduced by the Galilean transformation
to replace the fixed coordinates (x) with a moving coordinate system
(͂x), which is attached at the needle base and moves with it. vx is the
needle insertion velocity, which is assumed to be constant for modeling
simplicity.

The system kinetic energy T includes the kinetic energy of the fixture
and the needle, as shown in the first and second terms of the following
equation (3), while the potential energy V includes the potential energy
of the needle caused by needle bending (the first term) and the potential
energy of the springs resulting from the forces between the needle and the
tissue (the second term), as given in (4). The integration of the difference
between the needle body positions and the needle tip trajectory gives the
summation of the elongated or compressed spring length (decided by
the sign of the difference) at the contact points. Because only the needle
portion inside the tissue has springs exerting force on it (5), the Heaviside
unit step function is used to exclude the portion outside the tissue.
h(x) = L - vx t is the position of the insertion point in the moving
coordinates system at time instant t. Thus, the potential energy of the
springs can be calculated using the second term of (4)

A. Needle Lateral Steering Force Modeling
A spring–beam–damper system, as shown in Fig. 1, is considered in
this study to model the system dynamics between the lateral steering
forces acting at the needle base and the corresponding needle tip lateral
movement during insertion in the soft tissue. The flexible needle is
assumed to follow the Bernoulli–Euler beam model and is required to
be clamped tightly at the base. The initial lengths of springs are decided
by the needle tip trajectory, as shown in the figure. At the beginning, the
needle is placed next to the tissue. With time progressing on, the needle
inserts into the tissue. Then, the springs and dampers come into contact
with the needles and exert forces on it accordingly. The forces of the
springs at time instant t are determined by the needle body shape at that
time and the needle tip trajectory; while the forces of the dampers are
determined by the velocities of the contact points. During this procedure,
not only the tissue deformation and the needle flexibility, but also their
interaction effects, should be taken into consideration.
To derive the equations of needle insertion, the following assumptions
are made.
1) For simplicity, the needle is considered to move only in the XY
plane. X is the insertion direction and Y is the steering direction.
2) There is no longitudinal compression of the beam and only lateral
deflection is possible. Furthermore, the lateral deflection of the
beam is small compared with the length of the beam.
3) The rotational effect of the beam with respect to the local coordinate
system is neglected.
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Here, M is the mass of the fixture that links the needle with the 3-D
motion platform, L is the length of the elastic beam, ρ is the mass per unit
length of the elastic beam, E is the Young’s modulus of the needle, I is the
second moment of inertia about the z-axis, k is the stiffness coefficient
of the spring per unit length, c is the damper coefficient per unit length,
⋅ is the corresponding velocity
y is the needle base position in y-axis, y(t)
at time instant t, ω is the deflection of the beam along the needle body at
time instance t, and ω⋅ and ω″ are the first and second derivatives of the
beam deflection with respect to time and space, respectively.

After some algebraic manipulation (refer to [22] for more details), the
model is finally obtained as follows:

The virtual work done by all the nonconservative forces (steering force Fy
and damping forces), is given by

The equation of motion and the boundary conditions of the system are
obtained by substituting the aforesaid equations (3), (4), and (6) into (1),
integrating the resulting equation by parts, and considering that the time
t1 and t2 are arbitrary and that δy, δω are arbitrary and independent.
Thus, the equations of motion for the spring–damper system are obtained
as follows:

with

where
Boundary conditions:

To solve the partial differential equations shown in (7) and (8),
unconstrained modal analysis is adopted in this approach.21 The
deflection of the elastic beam and the displacement of the fixture are
expressed, respectively, in terms of n mode shapes using the obtained
φ(͂x), βi, qi (t) as follows:

and accordingly, the position of fixture is given as

where α(t) describes the motion of the center of mass of the total system
without perturbation, ϕ(͂x) is the shape function that is the space solution
of the deflection, q(t) is the time-varying amplitude of motion that is the
time solution of the deflection, and β is defined to satisfy
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Here, Mt is the total mass of the fixture and needle; Y (t1) =
is the needle tip position at time instant t1,
which is time varying and derived from (10)–(12); and Fy is the lateral
steering force, which acts at the needle base in the y direction.
These partial differential equations can be solved using the explicit
Runge–Kutta (4, 5) formula, and the Dormand–Prince pair. A Matlab
simulation program has been composed to simulate this model. With the
applied needle base force Fy serving as the input of the model, α and qi
will change with time, thus causing the change of the needle tip position
Y (t1) in the y-axis, which is the output of the model, as well as the tissue
reaction forces.
B. Local Polynomial Approximation of Depth-Varying Mean Parameters
Considering the inhomogeneous human tissue and the multiple tissue
layers that the needle will penetrate through during surgery, here we
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Figure 2. Local polynomial approximations of the parameter functions.
propose to use depth-varying mean parameters to calculate the spring/
damper reaction forces and use local polynomials to approximate the
depth-varying mean parameters.
Assumption 1: The spring and damper coefficients are different at
different depths of the tissue. At each insertion step, the spring/damper
effects along the needle body that is inside the tissue can be calculated
using mean spring/damper coefficients θ(s) = [c̄ k̄]T. These mean
coefficients will vary with each step.
This assumption takes into consideration the inhomogeneous human
tissue, and at the same time, releases the computation intensity by using
mean values to calculate the spring/damper forces along the needle body
at each insertion step. Furthermore, the adoption of the mean values
guarantees that θ(s) is continuously distributed regardless of the abrupt
change of the tissue properties, e.g., pathological changes of the tissue,
or multilayer insertion.

length of the segment and p is the order of
s0,j refers to the resetting depth at which the jth
local polynomial approximation for parameter
given by the sequence s0 = { s0,j } , j = 1 , . . . , n
is the kth depth derivative evaluated at

is the unknown constant vector and
is a column vector. Notice that
is constant only within each segment [s0,j , s0,j+1), and in general, differs
from one segment to another for the inhomogeneous tissue.
Therefore, it is possible to use (16) to approximate θij (s) more precisely
by choosing either a higher order polynomial, that is, p large, or a
smaller segment l, or both. If we partition the whole insertion length
into segments with the length of each segment equal to l, then the
depth-varying function θi(s) can be approximated by a number of
polynomials θij (s) located in each segment with constant coefficients
aijk, as shown in (16).
C. Online Parameter Estimator Design
The discretized needle steering model is considered here. The needle
steering force model can be reorganized as

where

Assumption 2: The depth-varying mean parameters θ(s) can be represented
by a series of local polynomial approximations in finite segments.
This can be justified using Taylor series expansion. Recall that the functions
θ(s) can be expanded around certain points s 0, as shown next. Here, θ(s) is
approximated by the first p + 1terms. The last term represents the error due
to the approximation

The measured output

From the aforesaid assumptions, we can divide the whole insertion length
into several segments and adopt piecewise continuous p-order differentiable
functions θij , i = 1, 2, j = 1, 2, . . . , n to represent the depth-varying mean
parameter θi(s), i = 1, 2 in each segment, as illustrated in Fig. 2. Here, the
index i refers to the ith parameter (spring or damper coefficient), while
the index j refers to the jth segment and n is the number of segments.
The S coordinate system is adopted for convenient representation of the
parameters. So, the polynomial approximation of θij is represented as

Here, y1 refers to the needle tip trajectory, while y2 is the needle base
trajectory that is measured to facilitate the computation of the system
state x.
After some algebraic manipulation, we can get

Rm is the unknown depth-varying mean parameter vector with an
additional constant 1.
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Substituting the polynomial approximations for the depth-varying mean
parameters, (19) can be represented as

Here, for simplicity, we select the same-order polynomials for the two
parameters.
The transformation between the s domain and x
͂ domain is given by

under the same assumption that the needle is inserted at constant
velocity.

To facilitate the computation of the dynamic equation, the dataset s 0 =
{ s 0, j } , j = 1, 2, . . . can be converted to the time domain using
In discretized form

Based on this approach, the modified least-square estimation with
covariance resetting and forgetting factor is adopted to estimate the
coefficients that take the form

where ϑ̂ is the estimated parameter vector, Z is the measurement, λ is the
forgetting factor, P is the covariance matrix, and K is the gain.

3DOF Motion
Platform
Aurora Field
Generator
5DOF Tracking
Needle

Force Sensor
Figure 3. Experimental setup.
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D. Lateral Steering Force Model Validation
1) Material and Method:
To validate the effectiveness of the proposed steering model, a physical
experiment has been carried out. The experimental setup, shown in
Fig. 3, is used to carry out the experiment. The 3-DOF motion platform
drives the needle into the phantom/animal organ following some
predesigned trajectory. A 6-DOF force/torque (F/T) sensor is mounted
at the needle base to measure the needle base force. The needle adopted
here is a 5-DOF MagTrax needle probe. It is a 130-mm-long needle and
has a sensor located at the stylet’s proximal symmetric tip. This needle
tip movement in the 5-DOF, except rotation about the needle axis, can
be observed in real time via an electromagnetic system called Aurora.
An “active” way of validating the proposed model by steering the needle
tip to a defined position is infeasible now, since it will require a steering
strategy, which is our future task. Instead, a “passive” way of validation
is adopted to show that the model could accurately predict the needle
tip trajectory when giving some inputs – needle-based lateral forces. The
detailed validation procedure is described as follows.
The needle is first driven into the prepared phantom by the 3-DOF platform
following some predetermined trajectories with various insertion speeds.
The needle tip/base positions and corresponding needle base force data
are collected during the procedure. These collected datasets are first
passed through a designed filter to remove the measurement noises and
smooth the data. After that, the filled datasets go through the online
parameter estimator to estimate the depth-varying mean parameters.
At the same time, the model is simulated using the online estimated
parameters and the collected dataset to predict the output, the needle
tip position. The output is then regulated using the collected output data
instead of the simulated ones during the simulation. This regulation
method can prevent the simulator from accumulating estimation errors,
which will gradually lead to the divergence of the estimation. At last, the
simulated outputs and the needle tip position data are compared with
the measured positions during experiments.
2) Preliminary Experiments in Tissue-Like Phantoms:
Phantoms made of different gelatin/water ratios were first adopted to
simulate the soft tissue, for it is easy to obtain and the properties are
easy to control and replicate. The needle was driven into the phantom
for 8 cm in the x-direction and 2 cm in the y-direction. The insertion
speed was set to be 8, 4, and 2 mm/s, respectively. The lateral speed was
chosen accordingly in order to keep the movements in x and y to start
and stop simultaneously.
Fifth-order polynomials were chosen to represent the spring and damper
coefficients. The initial coefficients were set to be [3 × 105 × ones
(6, 1); 2 × 106 × ones(6, 1); 1]. The initial covariance matrix was set to
be [1016 × eye(13, 12)zeros(13, 1)]. The forgetting factor was selected to
be 0.99. For comparison purpose, one segment was chosen first. Fig. 4
shows one typical example of the simulated output versus the measured
output. The corresponding measurement errors and the reconstructed
depth-varying mean spring/damper coefficients using the estimated
polynomial parameters are shown in Figs. 5–7.
To improve the tracking accuracy, two segments were chosen next.
The same initial settings were used as in the one-segment estimation.
The simulation errors of one-segment estimation and two-segment
estimation are compared and shown in Fig. 8. We can see that the overall
accuracy has improved when using two segments.
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In this set of gelatin experiments, fifth-order polynomials were adopted
for the spring and damper coefficients. Orders lower than fifth have
shown larger estimation errors; while orders larger than fifth can
give better accuracy, but no significant improvement. Dividing the
whole insertion depth into more segments will improve the overall
tracking accuracy, but not much improvement on the convergent
rate, as can be detected in Fig. 8. The large estimation errors at the
beginning were caused by poor initial estimation and the large sensor
noises due to the sudden oscillation of the sensors when the needle was

x 10-3
2

0.1
-4
0.05

-6
200

400

600

800

1000

0

-0.05

-0.1
0

100

200

300

400

500

600

700

800

900

BODINEJOURNAL

29

accelerated to penetrate into the phantom; the relatively large estimation
errors at the end were due to the erratic sensor output when the needle
was decelerated to stop. The adjustment of the initial estimation has been
found to be capable of decreasing the magnitude of the initial estimation
error but cannot give much improvement on the convergent rate. This
will be further investigated in later experiments.
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Research: Department of Radiation Oncology
Clinical Research Studies/Grants

Basic Research Studies/Grants

• Phase I Study of the Combination of Vorinostat and Radiation
Therapy for the Treatment of Patients with Brain Metastases.

• Role of PIDD (LRDD) in coordinating the p53 and NFkB
pathways’ response to genotoxic stress.

• A Phase I Study Evaluating the Safety, Tolerability and
Pharmaco-kinetics of ABT-888 in Combination with Whole
Brain Radiation Therapy in Subjects with Brain Metastases.

• Self-seeding and radiation therapy: A new strategy against
metastatic prostate cancer.

• A Phase II Study of Erlotinib (Tarceva) and Hypofractionated
Thoracic Radiotherapy for Patients with Advanced or
Inoperable Non-Small-Cell Lung Cancer.
• RTOG #0436: A Phase III Trial Evaluating the Addition of
Cetuximab to Paclitaxel, Cisplatin, and Radiation for Patients
with Esophageal Cancer Who are Treated Without Surgery.
• RTOG #0534: A Phase III Trial of Short Term Androgen
Deprivation with Pelvic Lymph Node or Prostate Bed Only
Radiotherapy (SPPORT) in Prostate Cancer Patients with a
Rising PSA after Radical Prostatectomy
• RTOG #0614: A Randomized, Phase III, Double-Blind,
Placebo-Controlled Trial of Memantine for Prevention of
Cognitive Dysfunction in Patients Receiving Whole-brain
Radiotherapy.
• RTOG #0825: Phase III Double-Blind, Placebo-Controlled
Trial of Conventional Concurrent Chemo-radiation and
Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant
Temozolomide in Patients with Newly Diagnosed Glioblastoma.

• Dynamic control and tumor tracking for high duty cycle
precise radiation therapy.
• Improvement of GBM control by combining the HDAC
inhibitor, Vorinostat, with radiation and Temozolomide.
• ACRIN Protocol 6688: PET Pre-and post treatment assessment for locally advanced non-small cell lung carcinoma.
• RTOG Group Member Agreement.
• Physicist Chair
• Deputy Group Chair
• Vice Chair Translational Research Program
• Ultrasound-encoded functional optical imaging.
• Improvement of local control in locally advanced prostate
cancer by combining the mTOR Inhibitor Temsirolimus
with ionizing radiation.
• Molecular determinants of glioblastoma response to
Temozolamide combined with AZD2171 and radiotherapy.
• Development and analysis of an infrastructure for review
of modern clinical trials that include radiotherapy analysis.

Support Groups
Call for more details
Jefferson Journaling: A Program for Women
Facing Cancer
We will provide you techniques and tools for journaling.
Join us and find out how journaling may help you to
reduce stress related to illness or everyday life. Please feel
free to invite a supportive family member or friend. Call
1-800-JEFF-NOW.
Buddy Program and Buddy-on-the-Spot
A program in which newly diagnosed cancer patients are
matched (by diagnosis, treatment, age, and gender) with a
trained cancer survivor for one-on-one telephone support;
on-site support in Radiation Oncology or Medical Oncology
Infusion. Call 215-955-8370.

Ongoing Programs
Every Thursday
Radiation Therapy Information Session
This education and support program is for individuals
receiving radiation therapy. It is recommended that people
attend this session either prior to starting or in the first few
weeks of treatment. Physical and psychosocial effects of
radiation therapy are discussed.
Time:
10 – 11 am
Location: Kimmel Cancer Center
Bodine Building, G-312
Simon Kramer Conference Room
111 S. 11th Street, Philadelphia, PA 19107

Reduce Stress and Live Better – A Program
for Women with Cancer
This research study focuses on learning skills for living
better with the stress of cancer. The program includes free
8-week cancer support programs for women, 21 years or
older, and diagnosed with cancer or a recurrence within
three years (including those in active treatment). Call
215-955-2881 or visit: www.jeffersonhospital.org/cim

You can find additional information on our programs and services for patients and their families at
www.JeffersonHospital.org/cancer/programs.html
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Answering the need that exists for a single reference to address
the practical issues of implementing image guided radiation
therapy (IGRT) into prostate cancer treatment, this text provides:

Contents Include:
• Overview and treatment guidelines for image-guided
treatment in prostate cancer management

• complete overview of new and exciting technologies

• Imaging modalities

• practical guidance on successfully employing IGRT to
improve patient outcomes

• Modeling potential benefits from IGRT
• Pelvic and prostate anatomy, implications for IGRT

• disease stage-specific recommendations which include
dosage, fractionation, target volume delineation, and tissue
tolerances

• Image-guided treatment planning and localization modalities
• Image-guidance: the urologist perspective

• latest novel approaches to radiotherapy of prostate cancer
that include intensity modulated radiation therapy (IMRT),
hypofractionated radiation therapy, and proton beam
radiation therapy

• IGRT in prostate cancer: focus on fiducials
• IGRT in prostate cancer: focus on BAT and ultrasound
• IGRT in prostate cancer: focus on adaptive therapy
• IGRT in postoperative RT for prostate cancer
• The use of image-guidance in prostate brachytherapy
• IGRT in prostate cancer: targeting pelvic lymph nodes
• Fractionation issues with IGRT for clinically localized
prostate cancer
• Image-guided proton beam radiotherapy
• Future developments: On-line dosimetric verification and
cone-beam RT planning and verification
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